ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Additional Paid-In Capital : $247.78 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Additional Paid-In Capital?

ASLAN Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 ($244.54 Mil) to Dec. 2023 ($243.79 Mil) but then increased from Dec. 2023 ($243.79 Mil) to Mar. 2024 ($247.78 Mil).

ASLAN Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 ($221.47 Mil) to Dec. 2022 ($223.91 Mil) and increased from Dec. 2022 ($223.91 Mil) to Dec. 2023 ($243.79 Mil).

ASLAN Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for ASLAN Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Additional Paid-In Capital Chart

ASLAN Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

116.50

123.58

221.47

223.91

243.79

ASLAN Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															243.95	242.23	244.54	243.79	247.78

ASLAN Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

ASLAN Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.